What Does Magenta Therapeutics Do?

Total employees3
HeadquartersCambridge
Founded2016

Magenta Therapeutics (formerly NASDAQ: MGTA) was a clinical-stage biotechnology company that focused on developing novel medicines to bring the curative power of stem cell transplant to more patients with autoimmune diseases, blood cancers, and genetic diseases. The company's programs aimed to improve patient conditioning, stem cell mobilization, and cell engraftment. In early 2023, Magenta Therapeutics announced the discontinuation of its programs, including its lead candidate MGTA-117, following a patient death in a clinical trial. Subsequently, the company underwent a significant restructuring, workforce reduction, and ultimately pursued a plan of complete dissolution and liquidation.

Where Is Magenta Therapeutics's Headquarters?

HQ Function

The Cambridge headquarters served as the central hub for Magenta Therapeutics' research and development, clinical operations, and corporate functions before the company ceased operations.

Notable Features:

Located within Technology Square, a well-known campus for tech and life science companies, offering modern laboratory and office facilities.

Work Culture:

Prior to its dissolution, the work culture at Magenta Therapeutics was likely characterized by a strong focus on scientific innovation, collaboration, and a fast-paced environment typical of clinical-stage biotech companies aiming to address significant unmet medical needs. (Note: Company has ceased operations).

HQ Significance:

The Cambridge location provided strategic advantages, including proximity to world-class research institutions, a rich talent pool in biotechnology, and a vibrant ecosystem of collaborators and service providers.

Values Reflected in HQ: The choice of headquarters likely reflected the company's commitment to cutting-edge science, access to top talent, and being at the forefront of biomedical research within a leading global biotech cluster.

Location:

As a clinical-stage biotechnology company, Magenta Therapeutics' global presence was primarily through its clinical trial sites, which were conducted in collaboration with hospitals and research institutions in various countries. The company did not maintain a significant network of international offices for general business operations. All operations have ceased.

Street Address:

100 Technology Square, 5th Floor

City:

Cambridge

State/Province:

MA

Country:

USA

Where Else Does Magenta Therapeutics Operate Around the World?

No additional office locations available.

Buying Intent Signals for Magenta Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Magenta Therapeutics? Meet the Executive Team

As of April 2025, Magenta Therapeutics' leadership includes:

Jason Gardner, Ph.D. - Former President and Chief Executive Officer
Stephen Mahoney - Former Chief Operating Officer and Chief Business Officer
David Nichols, M.D. - Former Chief Medical Officer
Anne McGeorge - Former Chief Financial Officer
Michael Vasconcelles, M.D. - Former Chief Medical Officer (until mid-2022)

Who's Investing in Magenta Therapeutics?

Magenta Therapeutics has been backed by several prominent investors over the years, including:

Third Rock Ventures
Atlas Venture
GV (Google Ventures)
Casdin Capital
Access Biotechnology
Partner Fund Management
Beam Therapeutics (Strategic Partner/Investor)

What Leadership Changes Has Magenta Therapeutics Seen Recently?

Hire0
Exits4

The 12-18 months leading up to Magenta Therapeutics' dissolution in 2023 were marked by significant challenges, including clinical trial setbacks, which ultimately led to the departure of its executive team as part of the company's wind-down.

Departures

Jason Gardner, Ph.D., Stepped down in conjunction with the wind-down of company operations.
Stephen Mahoney, Stepped down in conjunction with the wind-down of company operations.
David Nichols, M.D., Stepped down in conjunction with the wind-down of company operations.
Anne McGeorge, Stepped down in conjunction with the wind-down of company operations.

What Technology (Tech Stack) Is Used byMagenta Therapeutics?

Discover the tools Magenta Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Magenta Therapeutics Email Formats and Examples

Based on common patterns for companies of its size and industry, Magenta Therapeutics likely used standard email formats. These email addresses are no longer active due to the company's cessation of operations.

jdoe@magentatx.com (first_initial)(last) or jane.doe@magentatx.com (first).(last)

Format

example@magentatx.com

Example

0%

Success rate

What's the Latest News About Magenta Therapeutics?

GlobeNewswireApril 27, 2023

Magenta Therapeutics News: Magenta Therapeutics Announces Plan of Complete Dissolution and Liquidation

Magenta Therapeutics announced that its Board of Directors approved a plan of complete dissolution and liquidation of the Company. This decision followed a comprehensive review of strategic alternatives after the company discontinued its clinical programs....more

Fierce BiotechFebruary 10, 2023

Magenta Therapeutics News: Magenta Therapeutics implodes, halting all programs and seeking 'strategic alternatives' after patient death

Magenta Therapeutics announced it was halting all further development of its programs, including its lead antibody-drug conjugate MGTA-117, following a patient death in a Phase I/II trial. The company also stated it would explore strategic alternatives and implement a significant workforce reduction....more

BioSpaceJanuary 26, 2023

Magenta Therapeutics News: Magenta Reports Patient Death in Phase I/II AML Trial, Halts Dosing of MGTA-117

Magenta Therapeutics reported that a patient dosed with MGTA-117 in its Phase I/II study in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) had died. As a result, the company voluntarily paused dosing in the trial to review the event....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Magenta Therapeutics, are just a search away.